Despite the emergence of new medicines to treat the disease, the country’s existing health system offers little help in reducing the suffering of patients.

The World Health Organization’s (WHO) recently released Global Tuberculosis Report for 2021 paints a dismal picture of the impact that the COVID-19 pandemic has had on the fight against TB across the globe.

Montreal, November 1^st, 2021 - Regular community-wide screening for active and latent tuberculosis (TB) appears to be cost-effective in Inuit communities with high TB rates and is recommended to help reduce outbreaks, according to new research published today in CMAJ (Canadian Medical Association Journal). The study was led by Dr. Kevin Schwartzman, Director of the Division of Respiratory Medicine at the McGill University Health Centre (MUHC) and Senior Scientist in the Translational Research in Respiratory Diseases Program at the Research Institute of the MUHC (RI-MUHC).

The University of Auckland, London School of Hygiene and Tropical Medicine, and the University College London, are conducting a short 10-minute survey on behalf of the World Health Organization (WHO), on user preferences of TB skin testing to inform the upcoming WHO TB testing guidelines. All people who wish to contribute are invited to complete the survey - you do not have to have experience of a skin test yourself. Of particular interest are the views of people with TB, health providers and others involved in TB care such as lab technicians and TB program managers.

The International Journal of Tuberculosis and Lung Disease (IJTLD) is the official publication of the International Union Against Tuberculosis and Lung Disease (The Union).

RESIST-TB released its October 2021 newsletter with the latest research publications on drug-resistant TB.

Given the complexity of multidrug-resistant TB (MDR-TB) diagnosis and care, a new study sought to address key knowledge gaps in MDR risk factors, care delays, and drivers of delay to help guide disease control.

On 4 November 2021, Treatment Action Group (TAG) and the International Treatment Preparedness Coalition (ITPC) will co-host a webinar, 'Same Meds, New Patents: What Do Activists Need to Know About Long-Acting Technologies', to present the main findings of the upcoming report 'Hepatitis C and Tuberculosis Long-Acting Medicines: Analysis on Patenting Trends.'

New data published by the UK Health Security Agency shows reported cases of TB fell in England in 2020, reducing rates from 8.4 per 100,000 in 2019 to 7.3 per 100,000.

This new resource provides activists with information about two shorter treatment regimens for drug-sensitive TB, and equips them with actions they can take and arguments they can use to advocate for access to those regimens.